Antiangiogenic treatment with endostatin inhibits progression of AML in vivo

Increased vessel density in the bone marrow of patients with acute myeloid leukemia as well as elevated expression of proangiogenic factors by leukemic cells implies a central role of angiogenesis in hematological malignancies. Endostatin (ES), a fragment of collagen XVIII, is an endogenous inhibitor of angiogenesis that has shown therapeutic activity in solid tumors in various preclinical models. Using microencapsulation technology, we studied the therapeutic effect of ES in AML. While ES had no effect on proliferation of M1 murine leukemic cells in vitro, ES producing microbeads significantly inhibited growth of subcutaneous chloromas in SCID mice as compared to controls. In a leukemia model using M1 cells the concomitant treatment of mice with ES microbeads prolonged median survival significantly. Histological analysis revealed a decreased microvessel density and a reduced number of CD31-positive single cells, putatively endothelial progenitor cells, in the bone marrow of treated animals. Taken together, ES has inhibitory effects on neo-angiogenesis in the bone marrow and on progression of leukemia in vivo. These experiments suggest a possible therapeutic role of antiangiogenic gene therapy with ES in AML.

[1]  H. Serve,et al.  Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia , 2002, Leukemia.

[2]  F. Cavalli,et al.  A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.

[3]  E. Estey,et al.  Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes , 2002, Cancer.

[4]  R. D'Amato,et al.  Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.

[5]  M. Yi,et al.  Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Ergün,et al.  Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia , 1997, Leukemia.

[7]  S. Rafii,et al.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.

[8]  S. Ergün,et al.  Methods to evaluate the formation and stabilization of blood vessels and their role in tumor growth and metastasis. , 2001, Methods in molecular medicine.

[9]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[10]  J. Folkman,et al.  Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. , 2000, Cancer research.

[11]  J. Folkman,et al.  Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes , 2004, Angiogenesis.

[12]  Ø. Bruserud,et al.  Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts , 2003, European journal of haematology.

[13]  G. Pruneri,et al.  Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. , 2000, Blood.

[14]  K. Alitalo,et al.  Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. , 2002, Cancer research.

[15]  M. Beksac,et al.  Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival , 2004, Leukemia & lymphoma.

[16]  Dane Dickson,et al.  Angiogenesis in Acute and Chronic Leukemias , 2001, Leukemia & lymphoma.

[17]  D. Qian,et al.  Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias , 2004, Clinical Cancer Research.

[18]  V. Sukhatme,et al.  Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. , 1999, Cancer research.

[19]  W. Berdel,et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. , 2000, Blood.

[20]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[21]  G. Nolan,et al.  Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  J. Debus,et al.  Endostatin's antiangiogenic signaling network. , 2004, Molecular cell.

[23]  D. Sørensen,et al.  Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias , 2002, Leukemia.

[24]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[25]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[26]  N. Miyake,et al.  Antiangiogenic gene therapy of myeloproliferative disease developed in transgenic mice expressing P230 bcr/abl , 2005, Gene Therapy.

[27]  J. Folkman,et al.  Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. , 2003, Cancer research.

[28]  U. Gehling,et al.  Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  V. Sukhatme,et al.  Endostatin Causes G1 Arrest of Endothelial Cells through Inhibition of Cyclin D1* , 2002, The Journal of Biological Chemistry.

[30]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[31]  E. Estey,et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.

[32]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[33]  C. Eaves,et al.  Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  C. Löwik,et al.  Effect of Angiogenic and Antiangiogenic Compounds on the Outgrowth of Capillary Structures from Fetal Mouse Bone Explants , 2001, Laboratory Investigation.

[35]  M. Gondo,et al.  Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene , 1999, Nature Biotechnology.

[36]  Anthony Atala,et al.  Continuous release of endostatin from microencapsulated engineered cells for tumor therapy , 2001, Nature Biotechnology.

[37]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[38]  A. Feller,et al.  Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. , 2002, Leukemia research.

[39]  Y. Gho,et al.  Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1* , 2002, The Journal of Biological Chemistry.

[40]  R. Timpl,et al.  Local endostatin treatment of gliomas administered by microencapsulated producer cells , 2001, Nature Biotechnology.

[41]  T. Grogan,et al.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.

[42]  G. Rodgers,et al.  Evidence of increased angiogenesis in patients with acute myeloid leukemia. , 2000, Blood.

[43]  S. Donnini,et al.  Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  S. Ergün,et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. , 1997, Blood.

[45]  Giovanni Martinelli,et al.  Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.